Lung Cancer (NSCLC)

Oncology·MeSH: Lung Neoplasms

Prevalence

30.0 / 100K

83 drugs in development·49 companies·7 clinical trials

Drug Pipeline by Phase

Approved(14)

Drug	Company
Alimta®	ELI LILLY & Co (LLY)
Cyramza	ELI LILLY & Co (LLY)
docetaxel	Amneal Pharmaceuticals, Inc. (AMRX)
emrelis	AbbVie Inc. (ABBV)
gavreto	RIGEL PHARMACEUTICALS INC (RIGL)
krazati	BRISTOL MYERS SQUIBB CO (BMY)
lorbrena	PFIZER INC (PFE)
opdivo qvantig	BRISTOL MYERS SQUIBB CO (BMY)
paclitaxel	Mylan II B.V. (MYL)
pemetrexed	DR REDDYS LABORATORIES LTD (RDY)
pemfexy	EAGLE PHARMACEUTICALS, INC. (EGRX)
portrazza	ELI LILLY & Co (LLY)
vizimpro	PFIZER INC (PFE)
Zenocutuzumab (Zeno) / BIZENGRI® (zenocutuzumab-zbco)	Merus N.V. (MRUS)

Phase 3(28)

Drug	Company
abp 234	AMGEN INC (AMGN)
aumolertinib	EQRx, Inc. (EQRX)
azacytidine	Merus N.V. (MRUS)
AZD2936	ASTRAZENECA PLC (AZN)
CAN-2409	Candel Therapeutics, Inc. (CADL)
daraxonrasib	REVOLUTION MEDICINES, INC. (RVMD)
eftilagimod alfa	Immutep Limited (IMMP)
eftilagimod alfa	IMMUTEP Ltd (PRRUF)
Eftilagimod Alfa	Immutep Limited (IMMP)
elironrasib	REVOLUTION MEDICINES, INC. (RVMD)
furmonertinib	ArriVent BioPharma, Inc. (AVBP)
MEDI5752	ASTRAZENECA PLC (AZN)
olafertinib	Checkpoint Therapeutics, Inc. (CKPT)
Osimertinib	Crinetics Pharmaceuticals, Inc. (CRNX)
Pemetrexed	Merck & Co., Inc. (MRK)
Plinabulin	BeyondSpring Inc. (BYSI)
rmc-6236	REVOLUTION MEDICINES, INC. (RVMD)
rmc-6291	REVOLUTION MEDICINES, INC. (RVMD)
rmc-9805	REVOLUTION MEDICINES, INC. (RVMD)
Sacituzumab tirumotecan	Merck & Co., Inc. (MRK)
Sacituzumab tirumotecan	Merus N.V. (MRUS)
Supportive care measures	Merck & Co., Inc. (MRK)
tak-788	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tak-788	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
Taletrectinib	Nuvation Bio Inc. (NUVB)
Telisotuzumab vedotin	AbbVie Inc. (ABBV)
tsr-042	TESARO, Inc. (TSRO)
Zipalertinib (CLN-081/TAS6417)	Cullinan Therapeutics, Inc. (CGEM)

Phase 2(18)

Drug	Company
ABT-869 .25 mg/kg	AbbVie Inc. (ABBV)
ABT-869 0.10 mg/kg	AbbVie Inc. (ABBV)
am0010	ARMO BIOSCIENCES, INC. (ARMO)
amivantamab	ASTRAZENECA PLC (AZN)
BDTX-1535	Black Diamond Therapeutics, Inc. (BDTX)
capmatinib	Novartis AG (NVS)
capmatinib	Novartis AG (NVS)
cylembio	IO Biotech, Inc. (IOBT)
EOS-448	iTeos Therapeutics, Inc. (ITOS)
fs118	F-star Therapeutics, Inc. (FSTX)
Oleclumab	ASTRAZENECA PLC (AZN)
osimertinib	SUNSHINE BIOPHARMA INC. (SBFM)
Osimertinib alone	Crinetics Pharmaceuticals, Inc. (CRNX)
Pemetrexed	Merus N.V. (MRUS)
RP1	ENANTA PHARMACEUTICALS INC (ENTA)
rucosopasem manganese	Galera Therapeutics, Inc. (GRTX)
vintafolide	ENDOCYTE INC (ECYT)
wsd0922-fu	SUNSHINE BIOPHARMA INC. (SBFM)

Phase 1(13)

Drug	Company
ADCT-601	ADC Therapeutics SA (ADCT)
azacytidine	ENANTA PHARMACEUTICALS INC (ENTA)
AZD2936	Merus N.V. (MRUS)
Danvatirsen	Merus N.V. (MRUS)
Danvatirsen	ASTRAZENECA PLC (AZN)
deltacel	Kiromic Biopharma, Inc. (KRBP)
ec1456	ENDOCYTE INC (ECYT)
enozertinib	Oric Pharmaceuticals, Inc. (ORIC)
ko-2806	Kura Oncology, Inc. (KURA)
MEDI5752	Merus N.V. (MRUS)
Oleclumab	Merus N.V. (MRUS)
rmc-5127	REVOLUTION MEDICINES, INC. (RVMD)
Zidesamtinib	Nuvalent, Inc. (NUVL)

Preclinical(7)

Drug	Company
ATNM-400	Actinium Pharmaceuticals, Inc. (ATNM)
BP1003	BIO-PATH HOLDINGS, INC. (BPTH)
chi3l1 bsabs	Ocean Biomedical, Inc. (OCEA)
chi3l1 mab	Ocean Biomedical, Inc. (OCEA)
Fourth-Generation EGFR Inhibitor	Theseus Pharmaceuticals, Inc. (THRX)
fyarro + adagrasib	Whitehawk Therapeutics, Inc. (WHWK)
til	CELLULAR BIOMEDICINE GROUP, INC. (CMBG)

Early Phase 1(1)

Drug	Company
VTP-600	Barinthus Biotherapeutics plc. (BRNS)

Phase 1/Phase 2(1)

Drug	Company
cetuximab	REVOLUTION MEDICINES, INC. (RVMD)

Phase 4(1)

Drug	Company
osimertinib	ASTRAZENECA PLC (AZN)

BioSniper tracks 83 drugs in development for Lung Cancer (NSCLC) across 49 companies.

There are 7 clinical trials targeting Lung Cancer (NSCLC) tracked by BioSniper.

The estimated prevalence of Lung Cancer (NSCLC) is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.